How big is T2 Biosystems, Inc.?

As of Jun 18, T2 Biosystems, Inc. has a market capitalization of 3.65 million, with recent net sales of 7.68 million and a net profit of -42.95 million. The company's shareholder's funds were -28.04 million, and total assets amounted to 34.80 million.

Market Cap: As of Jun 18, T2 Biosystems, Inc. has a market capitalization of 3.65 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, T2 Biosystems reported net sales of 7.68 million and a net profit of -42.95 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company's shareholder's funds were -28.04 million, and total assets amounted to 34.80 million.

What does T2 Biosystems, Inc. do?

T2 Biosystems, Inc. is an in vitro diagnostics company focused on pathogen detection and biomarker analysis, with a market cap of $3.65 million and quarterly net sales of $2 million but a net loss of $10 million as of September 2024.

Overview: <BR>T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform for pathogen detection and biomarker analysis within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 2 Million (Quarterly Results - Sep 2024) <BR>Net Profit: -10 Million (Quarterly Results - Sep 2024) <BR>Market cap: USD 3.65 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: 378.83% <BR>Price to Book: -0.31<BR><BR>Contact Details: <BR>Address: 101 Hartwell Ave, LEXINGTON MA : 02421-3125 <BR>Tel: ['1 781 4571200', '1 415 9375406'] <BR>Fax: 1 781 3573080 <BR>Website: http://www.t2biosystems.com/

Should I buy, sell or hold T2 Biosystems, Inc.?

Who are in the management team of T2 Biosystems, Inc.?

As of March 2022, T2 Biosystems, Inc.'s management team includes Non-Executive Chairman John McDonough, CEO John Sperzel, Lead Independent Director John Cumming, and Independent Directors Seymour Liebman, Thierry Bernard, and David Elsbree. They oversee the company's strategic direction and operations.

As of March 2022, the management team of T2 Biosystems, Inc. includes the following individuals:<BR><BR>- Mr. John McDonough, who serves as the Non-Executive Chairman of the Board.<BR>- Mr. John Sperzel, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. John Cumming, who holds the position of Lead Independent Director.<BR>- Mr. Seymour Liebman, who is a Director.<BR>- Mr. Thierry Bernard, who serves as an Independent Director.<BR>- Mr. David Elsbree, who is also an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is T2 Biosystems, Inc. overvalued or undervalued?

As of July 8, 2024, T2 Biosystems, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to negative valuation ratios and a year-to-date return of -99.17%, significantly underperforming its peers and the S&P 500.

As of 8 July 2024, the valuation grade for T2 Biosystems, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is overvalued given its negative valuation ratios, including a price to book value of -0.36 and an EV to EBITDA of -0.38, both of which suggest substantial financial distress. Additionally, its peer comparison reveals that T2 Biosystems underperforms against competitors like Vicarious Surgical, Inc. with an EV to EBITDA of -0.2398 and Citius Pharmaceuticals, Inc. at -0.3855.<BR><BR>The stock has experienced drastic declines, with a year-to-date return of -99.17% compared to the S&P 500's positive return of 12.22%, further reinforcing the notion that T2 Biosystems is not only overvalued but also facing severe operational challenges.

Is T2 Biosystems, Inc. technically bullish or bearish?

As of August 25, 2025, T2 Biosystems, Inc. shows a mildly bearish trend with mixed technical signals, including mildly bullish MACD indicators but bearish daily moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -99.17%.

As of 25 August 2025, the technical trend for T2 Biosystems, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. The monthly RSI shows a bullish signal, but the daily moving averages remain bearish, suggesting short-term weakness. The Bollinger Bands are sideways on the weekly chart and mildly bearish on the monthly chart, indicating a lack of clear direction. KST is bearish on both weekly and monthly time frames, and Dow Theory shows no trend in either time frame.<BR><BR>In terms of performance, T2 Biosystems has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -99.17% compared to the S&P 500's 12.22%. This stark contrast highlights the ongoing challenges faced by the stock. Overall, the current technical stance is mildly bearish, with mixed signals across different indicators.